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E D I T O R I A L
A call for the appropriate application of clinical
pharmacological principles in the search for safe and
efficacious COVID-19 (SARS-COV-2) treatments
1 | ASCEPT-BPS STATEMENT ON COVID-19
(SARS-COV-2)
The rapid emergence of coronavirus disease 2019 (COVID-19) cau-
sed by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-
CoV-2) has led to remarkable efforts by the scientific communities
internationally to identify potential pharmacological treatments
through the rapid initiation of clinical trials of novel and/or re-
purposed regulatory authority-approved therapies. We greatly wel-
come the significant global effort to safely expedite trials. However,
we are concerned that many studies have not been of high quality
to generate clinically meaningful data to enable effective translation
to clinical practice. Identifying the “right” drug (or drug combina-
tions) is only the first step. Applying core clinical pharmacology prin-
ciples at all stages of research will help identify the right dose, the
right patient, and the right treatment protocol. We hope that by
setting out the principles outlined in this statement, efforts to find a
safe and efficacious treatment for COVID-19 will have the best
chance of success.
At the time of writing (dated 20/5/2020), over 1,000 clinical tri-
als are underway for the successful treatment of COVID-19 infec-
tions, with most trials testing remdesivir, hydroxychloroquine,
lopinavir/ritonavir and azithromycin separately or in combination.
Drug development to treat COVID-19 has mainly focused on antivi-
rals and immune modulators, with the logic that the early stages of
the disease are characterised by the viral infection/replication stage,
whereas the later, severe stage is characterised by the so-called
‘cytokine storm’. The later phase is experienced by a subset of
patients but is the major cause of fatalities.
The enthusiasm for antiviral agents has been driven by the suc-
cessful demonstration of in vitro antiviral efficacy using cell culture
experiments, often without concomitant studies in appropriate pre-
clinical species and at doses that may be unsafe or unachievable in
humans. Further, in vitro efficacy does not guarantee that a drug
will be efficacious and safe in humans using doses required to
achieve free drug concentrations at the sites of infection, even for
those agents already marketed for other indications. The
repurposing and trialling of immune modulatory agents, such as
those targeting IL6, TNF-α, IL1 and JAK, is because over-production
of pro-inflammatory cytokines has been implicated in tissue injury
(especially in the lungs), leading to multi-organ failure and death.
However, at this stage of the disease, we cannot exclude that the
virus itself is also responsible, either partly or wholly, for the organ
manifestations observed in COVID-19. It is therefore important that
treatment choice must be connected to understanding of disease
mechanism.
An understanding and application of the core principles of clini-
cal pharmacology can help researchers navigate the known chal-
lenges of drug discovery and development. These principles are
vital to support medication choice, clinical trial design, dose selec-
tion and dose individualisation, relative to the stage of viral infec-
tion. In this statement, we outline five core principles (Figure 1) to
ensure safety and efficacy of proposed treatments, some of which
are relevant to antiviral drug development only (principles 1 and 3),
while others apply to both antivirals and immune modulators (princi-
ples 2, 4 and 5). The aim of this statement is to provide benchmark
recommendations for those publishing results, reporting results or
developing clinical trials for the treatment of COVID-19. This is
essential to understand the public health impact of potential
COVID-19 treatments.
We suggest that alignment with the outlined principles should be
considered and reported when:
• Planning and communicating research studies including clinical tri-
als and non-interventional studies
• Reviewing and accepting manuscripts in scientific journals
• Making funding decisions related to COVID-19 research
• Interpreting and reporting research findings with all forms of media
• Producing patient and consumer information
• Developing and implementing policies by Governments and related
bodies to inform COVID-19 guideline recommendations and medi-
cation purchasing
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2 | CORE CLINICAL PHARMACOLOGY
PRINCIPLES AND RECOMMENDATIONS TO
OPTIMISE SAFETY AND EFFICACY OF
COVID-19 TREATMENTS
Principle 1
The drug demonstrates activity against the target virus in pre-clinical
studies at doses shown or predicted to be tolerated by humans.
Recommendations:
i The EC50 and/or EC90 (if available) for the target virus is reported
and standardised to molar units
ii Differences between cell culture system(s) relative to human
physiology are reported and critically evaluated. Two key issues
need to be addressed: a) the protein and its concentration in
assays is compared to circulating proteins in vivo (human) or pre-
clinical species, and, b) the type and function of cells utilised in
assays relative to the molecular target(s) that are key determi-
nants of viral ingress and replication, in particular, angiotensin-
converting enzyme 2 (ACE2) and transmembrane protease, serine
2 (TMPRSS2)
iii A proposed mechanism of action to inhibit viral replication is
reported which is biologically plausible while not causing apopto-
sis or an innate immune activation
iv Where an appropriate animal model is available, the activity of
the antiviral drug is shown in vivo in the model, even if this is
done in parallel with planning (and execution) of human studies.
At present, non-human animal models have been used for investi-
gating viral dynamics and immunity, but do not necessarily repli-
cate all the features of COVID-19 infection in humans such as
the inflammatory processes
Principle 2
The optimal concentrations of antiviral and immunomodulatory drugs
can be achieved for the proposed therapy in the relevant
compartment(s) (plasma, cells and tissues).
Recommendations:
i Human Plasma: demonstrate that the target unbound antiviral
drug concentration is achievable by:
F IGURE 1 The core principles and
recommendations to ensure that the safety and
efficacy of COVID-19 treatments is optimised. In
a pandemic situation, some of these activities
may need to be undertaken in parallel
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 Comparing the in-vivo EC50 and/or EC90 of the registered pri-
mary indication to the in-vitro viral EC50 and/or EC90
standardised to molar units
 Comparing the measured free antiviral drug concentration at
the regulatory approved dose and frequency to in-vitro viral
EC50 and/or EC90 standardised to molar units. This may also
be obtained from population pharmacokinetic (PopPK) or
Physiologically Based Pharmacokinetic (PBPK) models avail-
able from regulatory approvals or scientific publications
ii Target Human Tissue: demonstrate that the unbound antiviral
drug concentration is achievable in the target human tissue by:
 Comparing the measured tissue drug concentration at the reg-
ulatory approved dose and frequency to the in-vitro viral EC50
and/or EC90 standardised to molar units
 Comparing the predicted drug concentration in tissues using
PBPK models at the regulatory approved dose and frequency
to in-vitro viral EC50 and/or EC90 standardised to molar units
iii Use in-silico quantitative pharmacology methods to simulate
unbound plasma and, where appropriate, tissue concentration
profiles of antivirals and immune modulators, including under-
standing the likely differences in key special populations where
further dose individualisation may be needed (e.g. pregnant
women, children, people with immunosuppression or chronic dis-
eases, older adults)
 For antivirals, quantitation of the time at, or above, the
reported EC50 or EC90 for the SARS-CoV-2 virus should be
defined
 For drugs targeting the ‘cytokine storm’, quantitation of bind-
ing to either the unbound circulating cytokine and/or soluble
receptor must be understood and defined
iv Measure total (and if practical unbound) concentrations in blood
(and if practical tissue) of the proposed treatment during clinical
trials. These can be used to develop PK models of the time course
of drug concentrations in patients who have COVID-19
Principle 3
Quantification of in vivo viral dynamics and time course should be
undertaken concurrently (Figure 1).
Recommendations:
i Quantitate the viral life cycle using appropriate assays to
understand:
 Time of infection
 Time to symptom onset
 Time-course of viral load using a validated method (VK model)
 Time-course of viral shedding
 Time-course for increases in cytokines and other inflammatory
markers
 Time-course of disease progression during hospitalisation
using ordinal clinical scales such as SOFA and NEWS II
 Rates of hospitalisation
 Rates of ICU admissions
 Rates of mortality
 Rates of infection and time-course in different high-risk target
populations e.g. paediatrics, pregnancy, older people, the criti-
cally unwell.
 Likely isolation times and cross infection rates
 Time course to return to baseline physical and cognitive
function
ii Use data in step 3i, to develop quantitative viral kinetic
(VK) models using previously established regulatory approved
methodologies for influenza and respiratory syncytial virus (RSV)
iii Link VK models to PK models obtained in vivo in patients with
COVID-19 (see 2iv) or if these clinical studies are not available in
patients with another disease with a registered indication to pro-
duce PK-VK models to understand the key windows for treat-
ment (or prophylaxis) between infection and/or clinical symptom
development relative to the known biology of the proposed drug.
If clinical PK models are not available then in-silico quantitative
simulations may need to be used (see 2iii)
Principle 4
Demonstrate posology optimisation for antiviral and immunomodula-
tory drugs to ensure the appropriate intensity and timing of therapy.
Recommendations:
i Define the optimal drug dose(s) and frequency to achieve
unbound concentrations in plasma and tissue to maximise anti-
viral and/or disease suppressing activity.
 For antivirals, this will require that the time course of unbound
drug concentration accumulation at the site of infection is
optimised using quantitative pharmacology methods to obtain
optimal inhibition of viral growth relative to the stage of viral
infection
 For disease suppressing agents, this will require that the time
course of unbound drug concentration at the site of produc-
tion or action of the cytokine combined with known quantita-
tion of binding to either the unbound circulating cytokine
and/or soluble receptor to optimise dosing
ii Ensure the proposed drug exposure in plasma (unbound or total)
and where appropriate, tissues, is below the minimum toxic con-
centrations for humans
 Optimised dosing schedules which exceed current regulatory
approved doses or frequencies will require a full safety
assessment
 The likelihood of concentration-related adverse effects which
may be detrimental to the patient are understood, e.g. cardiac
toxicity such as QT prolongation, and appropriate monitoring,
dose adjustment recommendations and other risk mitigation
procedures are developed
iii Define the likelihood and extent of drug–drug PK and/or PD
interactions with concomitant medications used for treatment or
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support of the patient, and develop appropriate risk mitigation
procedures to minimise risk
iv Define dose adjustment for special populations to ensure safety
and efficacy
v Model informed simulations for the dose and dose frequency
linked to viral kinetics (PK-VK), or target mediated drug disposi-
tion for cytokine antibodies are essential for the development of
treatment arms within clinical trials to ensure the highest likeli-
hood of efficacy and safety
Principle 5
Robustly designed and innovative (e.g. adaptive) randomised con-
trolled trials should be used to determine efficacy and safety so that
the benefit-harm balance of treatments are identified, rather than
treatments being made solely available through compassionate use
programmes.
Recommendations:
i Leveraging prior knowledge from Phase I-II studies for the pri-
mary (or related) indications of the medication, it may be appro-
priate to progress directly to phase III trials. However, where
this information is not available, for example a new formulation
of a known drug, early Phase trials (I and II) should be under-
taken so that they form a pipeline of products to be tested in
Phase III
ii Treatments should be compared to standard of care (preferably
with placebo) in a randomised double-blind trial setting, even if
multiple doses are being trialled
iii Trials should be adequately powered taking into account the
stage and biology of the disease, and feasibility of undertaking
the trial, particularly in the context of an epidemic where num-
bers may be changing rapidly because of concurrent social con-
trol measures
iv Inclusion criteria should not be too broad within particular trial
to better define the populations in which the treatment will be
most suitable
v Core clinical outcome criteria such as those proposed by the
COMET initiative should be used in Phase III trials to enable
comparisons between different trials and act as an enabler for
meta-analyses. For earlier phase trials, the use of surrogate
measures may be appropriate, but these should be rigorously
justified
vi Given the complexity of COVID-19, it is likely that combination
therapies will be needed, at least in some patients. Thus, for tri-
als involving combination therapies, there should be clear justi-
fication for the choice and doses of the drugs used based on
disease biology, when they are started (simultaneously or
sequentially), and whether the combination is likely to be supe-
rior to each of the monotherapies
vii There should be thorough assessment of safety end-points in
all trials, including those due to drug–drug and drug-disease
interactions, to ensure there is a complete profile of the hazards
of the medicine, in relation to the benefits, at different stages
of the disease
viii Clinical trials should be undertaken within the appropriate
regional or national ethical and regulatory frameworks.
3 | OTHER POTENTIAL THERAPIES
A number of potential therapies are emerging (e.g. anticoagulants,
fibrinolytic agent, and agents that work on the renin angiotensin sys-
tem) as our understanding of the pathophysiology of COVID-19 and
the host response expands. The principles of rigorous scientific assess-
ment described above apply equally to these potential therapies.
4 | CONCLUSIONS
COVID-19 is having such an enormous impact on individuals,
populations, and on the economy. There is urgent need to develop
safe and efficacious treatments that can reduce morbidity and mortal-
ity, and restore societal norms. However, this should not come at the
expense of the quality of science and clinical medicine. In many
instances, the adoption of un-trialled and potentially dangerous treat-
ments (and combinations) has dominated the discourse and caused
patient harm. To better understand the scope of potential therapies,
we advocate that these five key clinical pharmacological principles
should be adopted by the scientific and clinical communities to
improve the development of safe and efficacious treatments for
SARS-CoV-2.
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